Celcuity Inc. (NASDAQ:CELC) Short Interest Update

Celcuity Inc. (NASDAQ:CELC) saw a significant decline in short interest in November. As of November 30th, there was short interest totalling 2,870,000 shares, a decline of 7.1% from the November 15th total of 3,090,000 shares. Based on an average daily volume of 263,800 shares, the days-to-cover ratio is presently 10.9 days.

Institutional Inflows and Outflows

Institutional investors have recently modified their holdings of the business. Barclays PLC grew its holdings in Celcuity by 567.6% in the third quarter. Barclays PLC now owns 53,605 shares of the company’s stock worth $800,000 after purchasing an additional 45,576 shares during the period. Geode Capital Management LLC raised its position in shares of Celcuity by 27.6% in the 3rd quarter. Geode Capital Management LLC now owns 630,369 shares of the company’s stock worth $9,401,000 after purchasing an additional 136,518 shares during the last quarter. Y Intercept Hong Kong Ltd bought a new position in Celcuity in the 3rd quarter worth about $205,000. XTX Topco Ltd purchased a new stake in Celcuity during the 3rd quarter valued at about $307,000. Finally, Wellington Management Group LLP purchased a new stake in shares of Celcuity during the third quarter valued at approximately $770,000. 63.33% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

CELC has been the topic of several analyst reports. Stifel Nicolaus upped their price target on Celcuity from $39.00 to $42.00 and gave the company a “buy” rating in a research report on Monday, October 7th. Needham & Company LLC reaffirmed a “buy” rating and set a $23.00 price target on shares of Celcuity in a research note on Friday, November 15th. HC Wainwright reaffirmed a “buy” rating and issued a $27.00 price objective on shares of Celcuity in a research note on Friday, November 15th. Finally, Lifesci Capital began coverage on Celcuity in a report on Monday, August 26th. They set an “outperform” rating and a $27.00 target price for the company. Six equities research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, Celcuity has a consensus rating of “Buy” and an average target price of $29.17.

Celcuity Stock Down 3.2 %

CELC traded down $0.40 during trading on Monday, reaching $12.12. The stock had a trading volume of 613,250 shares, compared to its average volume of 276,289. The company has a current ratio of 10.35, a quick ratio of 10.36 and a debt-to-equity ratio of 0.65. The company has a market capitalization of $450.02 million, a price-to-earnings ratio of -4.80 and a beta of 0.74. The stock’s 50 day moving average is $14.34 and its two-hundred day moving average is $15.48. Celcuity has a one year low of $11.51 and a one year high of $22.19.

About Celcuity

Celcuity Inc, a clinical stage biotechnology company, focuses on the development of targeted therapies for the treatment of various solid tumors in the United States. The company's CELsignia diagnostic platform uses a patient's living tumor cells to identify the specific abnormal cellular process driving a patient's cancer and the related targeted therapy for the treatment.